Monoclonal antibodies as reversible equilibrium carriers of radiopharmaceuticals

D. A. Goodwin, C. F. Meares, G. F. David, M. McTigue, M. J. McCall, J. M. Frincke, M. R. Stone, R. M. Bartholomew, J. P. Leung

Research output: Contribution to journalArticle

Abstract

We have prepared monoclonal antibodies (MoAbs) with the specific ability to bind metal chelates such as 111In benzyl EDTA. One, 10, 50 and 100 μg MoAb CHA255 Kb = 4 × 10E9 was complexed with 111In BLEDTA II, BLEDTA IV, and benzyl EDTA and injected i.v. in Balb/c mice with KHJJ tumor. The biological half-life by whole body counting was profoundly altered for all three compounds; from minutes to hours with 10 μg; to days with 100 μg. Tumor uptake increased 50 fold at 24 h with increasing MoAb but satisfactory tumor concentrations (3% per g) and tumor/blood ratios (1.8:1) were obtained with an amount equivalent to 7 mg for a human. Blood level and whole body activity were decreased 30-50% within 3 h or i.v. injection of a "flushing" dose of unlabeled indium benzyl EDTA, increasing tumor/blood ratios to 50:1.

Original languageEnglish (US)
Pages (from-to)383-391
Number of pages9
JournalInternational Journal of Radiation Applications and Instrumentation.
Volume13
Issue number4
DOIs
StatePublished - 1986

Fingerprint

Radiopharmaceuticals
Monoclonal Antibodies
Neoplasms
Whole-Body Counting
Indium
Half-Life
Metals
Injections
benzyl-EDTA

Cite this

Goodwin, D. A., Meares, C. F., David, G. F., McTigue, M., McCall, M. J., Frincke, J. M., ... Leung, J. P. (1986). Monoclonal antibodies as reversible equilibrium carriers of radiopharmaceuticals. International Journal of Radiation Applications and Instrumentation., 13(4), 383-391. https://doi.org/10.1016/0883-2897(86)90015-2

Monoclonal antibodies as reversible equilibrium carriers of radiopharmaceuticals. / Goodwin, D. A.; Meares, C. F.; David, G. F.; McTigue, M.; McCall, M. J.; Frincke, J. M.; Stone, M. R.; Bartholomew, R. M.; Leung, J. P.

In: International Journal of Radiation Applications and Instrumentation., Vol. 13, No. 4, 1986, p. 383-391.

Research output: Contribution to journalArticle

Goodwin, DA, Meares, CF, David, GF, McTigue, M, McCall, MJ, Frincke, JM, Stone, MR, Bartholomew, RM & Leung, JP 1986, 'Monoclonal antibodies as reversible equilibrium carriers of radiopharmaceuticals', International Journal of Radiation Applications and Instrumentation., vol. 13, no. 4, pp. 383-391. https://doi.org/10.1016/0883-2897(86)90015-2
Goodwin, D. A. ; Meares, C. F. ; David, G. F. ; McTigue, M. ; McCall, M. J. ; Frincke, J. M. ; Stone, M. R. ; Bartholomew, R. M. ; Leung, J. P. / Monoclonal antibodies as reversible equilibrium carriers of radiopharmaceuticals. In: International Journal of Radiation Applications and Instrumentation. 1986 ; Vol. 13, No. 4. pp. 383-391.
@article{dfd19a85610e468487db99212ac7bee7,
title = "Monoclonal antibodies as reversible equilibrium carriers of radiopharmaceuticals",
abstract = "We have prepared monoclonal antibodies (MoAbs) with the specific ability to bind metal chelates such as 111In benzyl EDTA. One, 10, 50 and 100 μg MoAb CHA255 Kb = 4 × 10E9 was complexed with 111In BLEDTA II, BLEDTA IV, and benzyl EDTA and injected i.v. in Balb/c mice with KHJJ tumor. The biological half-life by whole body counting was profoundly altered for all three compounds; from minutes to hours with 10 μg; to days with 100 μg. Tumor uptake increased 50 fold at 24 h with increasing MoAb but satisfactory tumor concentrations (3{\%} per g) and tumor/blood ratios (1.8:1) were obtained with an amount equivalent to 7 mg for a human. Blood level and whole body activity were decreased 30-50{\%} within 3 h or i.v. injection of a {"}flushing{"} dose of unlabeled indium benzyl EDTA, increasing tumor/blood ratios to 50:1.",
author = "Goodwin, {D. A.} and Meares, {C. F.} and David, {G. F.} and M. McTigue and McCall, {M. J.} and Frincke, {J. M.} and Stone, {M. R.} and Bartholomew, {R. M.} and Leung, {J. P.}",
year = "1986",
doi = "10.1016/0883-2897(86)90015-2",
language = "English (US)",
volume = "13",
pages = "383--391",
journal = "Nuclear Medicine and Biology",
issn = "0969-8051",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Monoclonal antibodies as reversible equilibrium carriers of radiopharmaceuticals

AU - Goodwin, D. A.

AU - Meares, C. F.

AU - David, G. F.

AU - McTigue, M.

AU - McCall, M. J.

AU - Frincke, J. M.

AU - Stone, M. R.

AU - Bartholomew, R. M.

AU - Leung, J. P.

PY - 1986

Y1 - 1986

N2 - We have prepared monoclonal antibodies (MoAbs) with the specific ability to bind metal chelates such as 111In benzyl EDTA. One, 10, 50 and 100 μg MoAb CHA255 Kb = 4 × 10E9 was complexed with 111In BLEDTA II, BLEDTA IV, and benzyl EDTA and injected i.v. in Balb/c mice with KHJJ tumor. The biological half-life by whole body counting was profoundly altered for all three compounds; from minutes to hours with 10 μg; to days with 100 μg. Tumor uptake increased 50 fold at 24 h with increasing MoAb but satisfactory tumor concentrations (3% per g) and tumor/blood ratios (1.8:1) were obtained with an amount equivalent to 7 mg for a human. Blood level and whole body activity were decreased 30-50% within 3 h or i.v. injection of a "flushing" dose of unlabeled indium benzyl EDTA, increasing tumor/blood ratios to 50:1.

AB - We have prepared monoclonal antibodies (MoAbs) with the specific ability to bind metal chelates such as 111In benzyl EDTA. One, 10, 50 and 100 μg MoAb CHA255 Kb = 4 × 10E9 was complexed with 111In BLEDTA II, BLEDTA IV, and benzyl EDTA and injected i.v. in Balb/c mice with KHJJ tumor. The biological half-life by whole body counting was profoundly altered for all three compounds; from minutes to hours with 10 μg; to days with 100 μg. Tumor uptake increased 50 fold at 24 h with increasing MoAb but satisfactory tumor concentrations (3% per g) and tumor/blood ratios (1.8:1) were obtained with an amount equivalent to 7 mg for a human. Blood level and whole body activity were decreased 30-50% within 3 h or i.v. injection of a "flushing" dose of unlabeled indium benzyl EDTA, increasing tumor/blood ratios to 50:1.

UR - http://www.scopus.com/inward/record.url?scp=14544280077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14544280077&partnerID=8YFLogxK

U2 - 10.1016/0883-2897(86)90015-2

DO - 10.1016/0883-2897(86)90015-2

M3 - Article

VL - 13

SP - 383

EP - 391

JO - Nuclear Medicine and Biology

JF - Nuclear Medicine and Biology

SN - 0969-8051

IS - 4

ER -